Geoff Cumming
Director/Board Member chez ANTEOTECH LIMITED
Fortune : 605 135 $ au 31/03/2024
Profil
Geoffrey James Cumming currently works at BARD1AG SA, as Chairman, AnteoTech Ltd., as Independent Non-Executive Director from 2016, Medical Australia Ltd., as Non-Executive Director from 2009, Multiple Sclerosis Research Australia Ltd., as Non-Executive Director, INOVIQ Ltd., as Non-Executive Director from 2023, and Australian Institute of Co. Directors, as Member.
Dr. Cumming also formerly worked at Biosceptre (Aust) Pty Ltd., as Chief Executive Officer & Managing Director, Biosceptre International Ltd., as Chief Executive Officer & Managing Director, BMDI Tuta Ltd., as Non-Executive Director in 2009, Roche Diagnostic Systems, Inc., as Managing Director-Oceania Regional Centre, Medical Australia Ltd., as Independent Non-Executive Director from 2011 to 2017, and Sienna Cancer Diagnostics Ltd., as Non-Executive Director in 2006.
Dr. Cumming received his undergraduate degree and doctorate degree from Monash University, Masters Business Admin degree from Macquarie University, and undergraduate degree from Swinburne University of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ANTEOTECH LTD
1,14% | 14/11/2023 | 25 067 750 ( 1,14% ) | 605 135 $ | 31/03/2024 |
Postes actifs de Geoff Cumming
| Sociétés | Poste | Début |
|---|---|---|
| ANTEOTECH LIMITED | Director/Board Member | 02/04/2009 |
| INOVIQ LTD | Director/Board Member | 29/11/2023 |
| MEDICAL AUSTRALIA LIMITED | Director/Board Member | 01/01/2009 |
Australian Institute of Co. Directors
 Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Corporate Officer/Principal | 21/02/2011 |
| Multiple Sclerosis Research Australia Ltd. | Director/Board Member | - |
BARD1AG SA
 BARD1AG SA Medical/Nursing ServicesHealth Services BARD1AG SA develops blood tests for the early detection of colorectal and lung cancer based on cancer-specific BARD1 isoforms. It offers screening and diagnosis services. The company was founded by Irmgard Irminger-Finger and Tony Walker in 2010 is headquartered in Geneva, Switzerland. | Chairman | - |
Anciens postes connus de Geoff Cumming
| Sociétés | Poste | Fin |
|---|---|---|
| MEDICAL AUSTRALIA LIMITED | Director/Board Member | 01/11/2017 |
BMDI Tuta Ltd.
 BMDI Tuta Ltd. Medical DistributorsDistribution Services BMDI Tuta Ltd. develops, manufactures, and distributes a range of medical devices. It offers medical systems, such as intravenous gravity and pump administration sets, extension sets, burettes, transfusion sets, specialty sets, needle-free devices, and infusion devices and equipment; and safety injection and collection products, which comprise AD syringes, and manual and auto-retractable safety syringes, medical waste containers, and needle disposal systems. The company is headquartered in Sydney, Australia. | Director/Board Member | 06/11/2009 |
Biosceptre International Ltd.
 Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The private company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Chief Executive Officer | - |
| ░░░░░░░░░░ ░░░░░░ ░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░ ░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░ | - |
Formation de Geoff Cumming
| Monash University | Doctorate Degree |
| Macquarie University | Masters Business Admin |
| Swinburne University of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ANTEOTECH LIMITED | Health Technology |
| INOVIQ LTD | Health Services |
| Entreprise privées | 9 |
|---|---|
Biosceptre (Aust) Pty Ltd.
 Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Commercial Services |
BMDI Tuta Ltd.
BMDI Tuta Ltd. Medical DistributorsDistribution Services BMDI Tuta Ltd. develops, manufactures, and distributes a range of medical devices. It offers medical systems, such as intravenous gravity and pump administration sets, extension sets, burettes, transfusion sets, specialty sets, needle-free devices, and infusion devices and equipment; and safety injection and collection products, which comprise AD syringes, and manual and auto-retractable safety syringes, medical waste containers, and needle disposal systems. The company is headquartered in Sydney, Australia. | Distribution Services |
Roche Diagnostic Systems, Inc.
 Roche Diagnostic Systems, Inc. Medical SpecialtiesHealth Technology Roche Diagnostic Systems, Inc. develops and manufactures diagnostic devices. The company is based in Indianapolis, IN. | Health Technology |
Medical Australia Ltd.
 Medical Australia Ltd. Medical SpecialtiesHealth Technology Medical Australia Pty Ltd. engages in the development, manufacture, and distribution of medical devices and consumables used in the human and animal healthcare markets. It offers medication delivery, reuse prevention, and surgical devices. It operates through the following geographical segments: Australia, Asia, New Zealand, and United Kingdom. The company was founded on February 28, 2001 and is headquartered in Lidcombe, Australia. | Health Technology |
| Multiple Sclerosis Research Australia Ltd. | |
Sienna Cancer Diagnostics Ltd.
 Sienna Cancer Diagnostics Ltd. BiotechnologyHealth Technology Sienna Cancer Diagnostics Ltd. operates as a medical technology company. It delivers sensitive, novel, robust and test for early detection of cancer, assessment of cancer treatments and assistance in drug development. The company was founded in 2002 and is headquartered in Scoresby, Australia. | Health Technology |
BARD1AG SA
BARD1AG SA Medical/Nursing ServicesHealth Services BARD1AG SA develops blood tests for the early detection of colorectal and lung cancer based on cancer-specific BARD1 isoforms. It offers screening and diagnosis services. The company was founded by Irmgard Irminger-Finger and Tony Walker in 2010 is headquartered in Geneva, Switzerland. | Health Services |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The private company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
